Citeline, Cytel Announce Strategic Partnership to Advance Clinical Trial Enrollment Planning

NEW YORK and CAMBRIDGE, MA – July 31, 2026 – Citeline, a Norstella company and leading provider of clinical, drug, and commercial intelligence for the life sciences industry, and Cytel Inc., a global leader in statistical software and advanced quantitative solutions for clinical development, today announced a strategic partnership to enhance clinical trial enrollment planning through the integration of Citeline's clinical trial intelligence with Enforesys® 4.0, the latest release of Cytel's enrollment forecasting and feasibility planning platform.

The partnership combines Cytel's expertise in simulation-based enrollment forecasting with Citeline's industry-leading clinical trial intelligence to help sponsors and CROs make more informed operational decisions, improve feasibility assessments, and better understand enrollment risk before studies begin.

Building on years of successful use across the pharmaceutical industry, Enforesys 4.0 expands the platform's capabilities by incorporating enriched clinical trial intelligence into its simulation-driven forecasting workflows. The result is a more robust approach to enrollment planning that enables clinical teams to evaluate uncertainty, compare recruitment strategies, and assess the probability of achieving critical enrollment milestones.

”The Citeline-Cytel partnership gives customers the best of both worlds,” said Suzanne Caruso, President, Clinical & Strategic Intelligence at Norstella’s Citeline. “They receive the forecasting and feasibility expertise of Cytel, plus our gold-standard Trialtrove and Sitetrove data. Together, we help remove the guesswork from clinical trial recruitment and enrollment.”

A More Intelligent Approach to Enrollment Forecasting

Patient recruitment remains one of the greatest challenges in clinical development. Traditional enrollment forecasts often rely on deterministic assumptions that fail to capture the variability inherent in real-world trial execution.

Enforesys 4.0 addresses this challenge by using advanced simulation methods to evaluate thousands of potential enrollment scenarios, optimizing for cost, duration and probability of technical success. Coupled with machine-learning algorithms to help organizations identify the best sites to achieve study objectives, the platform helps quantify the probability of achieving recruitment milestones while accounting for uncertainty across factors such as site activation timelines, enrollment rates, screening failures, site performance, and regional variability.

"Successful enrollment planning depends on both high-quality data and the ability to understand uncertainty," said Kevin Trimm, Chief Product Officer at Cytel. "For years, Enforesys has helped organizations make more informed decisions through simulation-based enrollment forecasting. By integrating Citeline's trusted clinical trial intelligence into Enforesys 4.0, we're giving customers richer inputs, more realistic scenarios, and greater confidence in their feasibility assessments and operational planning. Using Citeline’s continuously updated, comprehensive database is an important complement to single institution data sources to enable a more holistic patient recruitment landscape."

The integration of further strengthens these capabilities by providing site-level historical performance data to support realistic and indication-specific forecasting and study planning for mutual customers. By grounding simulations on current real-world performance data and models, Enforesys provides feasibility teams confidence in delivering critical development milestones. Combined with Enforesys dynamic reforecasting data integrations and alert system, development teams maintain a clear view on trial success from planning through execution in a single, unified platform.

Connecting Clinical Intelligence with Simulation Science

The strategic partnership reflects a shared commitment by Cytel and Citeline to support better decision-making throughout the clinical development lifecycle.

By bringing together trusted clinical trial intelligence with advanced simulation technology, the collaboration enables sponsors and CROs to move beyond static enrollment forecasts toward probability-based planning that better reflects the realities of clinical trial execution.

Building on a Proven Platform

Enforesys has long helped pharmaceutical companies and CROs forecast enrollment performance, evaluate study feasibility, and assess recruitment risk using advanced simulation methodologies.

Version 4.0 represents the next evolution of the platform, extending its capabilities through the integration of external clinical trial intelligence while continuing Cytel's commitment to delivering innovative software solutions that improve clinical development planning and execution.

About Citeline

Citeline, backed by the strength of Norstella — the AI company for biopharma's highest-stakes decisions — powers a full suite of complementary business intelligence offerings to meet the evolving needs of life science professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical-, commercial-, and regulatory-related decisions and create real-world opportunities for growth.    

Citeline’s global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical, and medtech industries, covering them all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts, and more. For more information on one of the world’s most trusted health science partners, visit Citeline and follow on LinkedIn and X.

About Cytel

Cytel is the world's leading provider of statistical software, advanced quantitative solutions, and statistical methods for the life sciences industry, committed to advancing human health. For nearly four decades, Cytel has helped biopharmaceutical organizations design, execute, and optimize clinical development programs through innovative software, scientific expertise, and data-driven decision-making. By accelerating development timelines, improving probability of success, and enabling better outcomes for patients, Cytel continues to advance the science of clinical research. For more information about Enforesys®, visit www.cytel.com.

Media Contacts

For Citeline – Laura Vellidis, Diffusion PR
[email protected]
(213) 318-4500

For Cytel - Sofie Vandevyver
VP, Global Head of Marketing
[email protected]